How many insider trades does FilingIQ track for MREO?

FilingIQ tracks 78 Form 4 insider transactions for MREO (Mereo BioPharma Group plc), covering filings from May 22, 2024 onwards. 14 of those were filed in the last 90 days.

Are MREO insiders net buyers or net sellers?

Across the full Form 4 history for MREO, 0 transactions (0%) were open-market purchases and 25 (32%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does MREO insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is MREO in?

Mereo BioPharma Group plc (MREO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $62.98M.

MREO insider trading

Healthcare

Mereo BioPharma Group plc — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 32%

Market cap

$62.98M

About Mereo BioPharma Group plc

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.

Company website: www.mereobiopharma.com

MREO insider activity at a glance

FilingIQ has scored 78 insider transactions for MREO since May 22, 2024. The most recent filing in our index is dated Feb 26, 2026.

Across the full history, 0 open-market purchases and 25 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on MREO insider trades is 61.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live MREO trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for MREO?: FilingIQ tracks 78 Form 4 insider transactions for MREO (Mereo BioPharma Group plc), covering filings from May 22, 2024 onwards. 14 of those were filed in the last 90 days.
Are MREO insiders net buyers or net sellers?: Across the full Form 4 history for MREO, 0 transactions (0%) were open-market purchases and 25 (32%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does MREO insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is MREO in?: Mereo BioPharma Group plc (MREO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $62.98M.

Methodology & sources

Every MREO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.